

RESEARCH

Open Access



# Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS): a longitudinal cohort study

Annelise Blomberg<sup>1,2\*</sup>, Jann Mortensen<sup>3,4</sup>, Pál Weihe<sup>5,6</sup> and Philippe Grandjean<sup>1,7</sup>

## Abstract

**Background** Environmental exposures to industrial chemicals, including perfluoroalkyl substances (PFAS), may play a role in bone development and future risk of osteoporosis. However, as prospective evidence is limited, the role of developmental PFAS exposures in bone density changes in childhood is unclear. The objective of this study was to estimate associations between serum-PFAS concentrations measured in infancy and early childhood and areal bone mineral density (aBMD) measured at age 9 years in a birth cohort of children from the Faroe Islands.

**Methods** We prospectively measured concentrations of five PFAS in cord serum and serum collected at 18 months, 5 years and 9 years, and conducted whole-body DXA scans at the 9-year clinical visit. Our study included 366 mother-child pairs with DXA scans and at least one PFAS measurement. We estimated covariate-adjusted associations of individual PFAS concentrations with age-, sex- and height-adjusted aBMD z-scores using multivariable regression models and applied formal mediation analysis to estimate the possible impact of by several measures of body composition. We also evaluated whether associations were modified by child sex.

**Results** We found PFAS exposures in childhood to be negatively associated with aBMD z-scores, with the strongest association seen for perfluorononanoic acid (PFNA) at age 5 years. A doubling in age-5 PFNA was associated with a 0.15 decrease in aBMD z-score (95% CI: -0.26, -0.039). The PFNA-aBMD association was significantly stronger in males than females, although effect modification by sex was not significant for other PFAS exposures. Results from the mediation analysis suggested that any potential associations between aBMD and 18-month PFAS concentrations may be mediated by total body fat and BMI, although most estimated total effects for PFAS exposures at age 18 months were non-significant. PFAS exposures at age 9 were not associated with age-9 aBMD z-scores.

**Conclusions** The PFAS-aBMD associations identified in this and previous studies suggest that bone may be a target tissue for PFAS. Pediatric bone density has been demonstrated to strongly track through young adulthood and possibly beyond; therefore, these prospective results may have important public health implications.

**Keywords** Per- and polyfluoroalkyl substances, PFAS, DXA, Childhood, Bone mass density

\*Correspondence:

Annelise Blomberg  
annelise.blomberg@med.lu.se

<sup>1</sup> Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA

<sup>2</sup> Division of Occupational and Environmental Medicine, Lund University, Scheelevägen 2, 22363 Lund, Sweden

<sup>3</sup> Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

<sup>4</sup> Department of Medicine, The Faroese National Hospital, Torshavn, Faroe Islands

<sup>5</sup> Department of Occupational Medicine and Public Health, Faroese Hospital System, Torshavn, Faroe Islands

<sup>6</sup> Center of Health Science, University of the Faroe Islands, Torshavn, Faroe Islands

<sup>7</sup> Department of Environmental Medicine, University of Southern Denmark, Odense, Denmark



© The Author(s) 2022, corrected publication 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Introduction

Perfluoroalkyl substances (PFAS) constitute a class of synthetic perfluorinated chemicals that are widespread in the environment and detectable in most human blood samples [1]. PFAS have been detected in human bone [2, 3], and toxicological studies suggest that PFAS exposure may alter bone ossification and accrual [4, 5]. Several cross-sectional epidemiological studies in adults have found associations between PFAS exposures and measures of bone health [6–10], and one study also found an association between baseline plasma PFAS concentrations and reductions in bone mass density over a 2-year period in overweight adults [8].

Given this evidence, the question arises if PFAS may induce changes in bone structure beginning in childhood. Bone mass accrues through childhood and adolescence until peak bone mass is reached by early adulthood [11]. This peak bone mass is an important determinant of future risk of osteoporosis [12, 13]. Bone development in infancy and childhood may be particularly vulnerable to chemical disruption. Because PFAS are endocrine disruptors, developmental PFAS exposures may alter the hormonal regulation of skeletal formation and the bone remodeling process and ultimately impact peak bone mass [14].

Five epidemiological studies to date have investigated a possible association between PFAS exposures and bone density in childhood and adolescence. Two cross-sectional studies evaluated associations at approximately 8 years of age. While the smaller of these studies only found suggestive inverse associations [15], the larger study reported that higher concentrations of PFOA, PFOS and the overall PFAS mixture were associated with lower areal bone mineral density (aBMD) z-scores [16]. A third cross-sectional study in NHANES adolescents ages 12–19 years found that PFOA and the overall PFAS mixture were similarly associated with lower aBMD z-scores in males but not females [17]. In addition, two prospective studies evaluated associations between maternal serum concentrations collected during pregnancy and indicators of bone health in older childhood [18] and adolescence [19], and identified some inverse associations.

However, each of these studies only included PFAS concentrations measured at one point in time (either prenatally or in mid-childhood), and therefore were unable to evaluate whether specific periods of bone development may be more susceptible to PFAS exposure. In addition, these studies differed in how they accounted for the role of body composition in a possible PFAS-bone association. While one study adjusted for height and lean body mass [19] and three others used height-adjusted aBMD z-scores as their primary outcome [16–18], one did not

adjust for any measure of body composition, arguing that it may be on the causal pathway [15]. This connection is important because previous research has demonstrated that body composition, including fat mass, is an important determinant of childhood bone mass [20, 21]. Furthermore, several studies have also identified associations between PFAS exposures and childhood adiposity [22–24]. Mediation analysis can be used to formally investigate potential influence by body composition and may yield insight into biological mechanisms underlying any observed associations.

To address the possible impact of developmental PFAS exposures on skeletal development during childhood, we studied the associations of repeated measures of serum-PFAS concentrations with aBMD at age 9 years in a birth cohort of children from the Faroe Islands, a community with wide ranges of PFAS exposures and fairly uniform social conditions and genetic background [25]. We estimated the total effect of PFAS exposure on aBMD and used a formal mediation analysis to assess the possible impact of body composition. We hypothesized that PFAS exposures would be associated with reduced bone mass density, but that part of this total effect might be mediated by changes in body composition during childhood growth.

## Methods

### Study population and design

The Faroese Cohort 5 includes 490 full-term singleton children and their mothers. Participants were consecutively recruited at the National Hospital in Tórshavn, Faroe Islands between October 2007 and April 2009 [26, 27]. A pregnancy questionnaire included questions on medical history, current health, diet, and social factors before and during pregnancy. Obstetric information on parity and pre-pregnancy weight and height were extracted from medical records. We collected umbilical cord blood samples immediately after birth. The cohort children were then invited for follow-up visits at ages 18 months, 5 years and 9 years. Each follow-up included a clinical examination, measurements of height and weight, blood sampling, and completion of a standard questionnaire. At 18 months, the questionnaire included questions about the duration of breastfeeding, and at 9 years the questionnaire included questions about diet and physical activity (estimated as the average number of non-school hours per week spent exercising or playing). A study selection flow chart is included in the Supplementary Material as Fig. S1. This study included a total of 366 participants with the necessary exposure, outcome, and covariate information.

The Harvard T.H. Chan institutional review board and Faroese ethical review committee approved the study

protocol, and written informed consent was obtained from all mothers.

### Exposure assessment

We measured concentrations of five major PFAS compounds (PFOS, PFOA, perfluorononanoic acid (PFNA), perfluorohexanesulfonic acid (PFHxS), and perfluorodecanoic acid (PFDA)) in serum obtained from cord blood at birth and at the 18-month, 5-year and 9-year clinical examinations. Samples were frozen shortly after separation and stored at  $-80^{\circ}\text{C}$ . PFAS concentrations were measured using online solid-phase extraction followed by high-pressure liquid chromatography with tandem mass spectrometry (LC-MS/MS) [28] at the Unit of Environmental Medicine, Institute of Public Health, University of Southern Denmark. All PFAS had a limit of detection (LOD) of 0.03 ng/ml. Samples with concentrations below the LOD were assigned a concentration of 0.015 ng/ml. Measurement imprecision was assessed by within-batch and between-batch coefficients of variation, which were  $<3\%$  and 5–6% respectively. The laboratory regularly participates in the German External Quality Assessment Scheme (G-EQUAS), organized by the German Society of Occupational Medicine, to ensure quality at a high level.

### Outcome assessment

We conducted whole-body DXA scans of subjects at the 9-year clinical visit using the Norland XR-800 system (Norland, Fort Atkinson WI, USA). Total body fat and lean mass were also measured in the same DXA scans. The system was calibrated daily. Quality control was performed using a QA Calibration Standard and a QC Phantom (BMD: 0.867 g/cm<sup>2</sup>; fat mass: 437.89 g; lean mass: 604.71 g) (Norland, Fort Atkinson WI, USA). Whole body scan precision (coefficient of variation (CV)) for BMC, aBMD and area was 0.67, 0.78 and 0.66%, respectively. The CV for lean mass and fat mass was 0.93 and 1.4%. Data were analyzed using the Illuminatus DXA software (Norland, Fort Atkinson WI, USA). We then calculated aBMD excluding the head (total body less head, TBLH) and used a reference dataset to derive age-, sex-, and height-adjusted TBLH aBMD *z*-scores (hereafter referred to as aBMD *z*-scores) [29], as is recommended by the International Society for Clinical Densitometry (ISCD) [30].

### Statistical analyses

We estimated the total associations between individual serum PFAS concentrations and aBMD *z*-scores using multivariable regression models. PFAS concentrations were natural log-transformed to minimize the impact of outlier values. The outcome, aBMD *z*-score, was normally

distributed and modeled as a continuous variable. Associations are reported as the expected difference in aBMD *z*-score for a doubling in the serum-PFAS concentration.

Models were adjusted a priori for covariates that have been associated with maternal or child PFAS concentrations in previous studies [31–36] and may also be associated with aBMD [37–39]. All models were adjusted for child sex, maternal smoking during pregnancy (yes, no), maternal pre-pregnancy BMI (kg/m<sup>2</sup>), parity (primiparous, multiparous), and maternal education (low, medium, high) as a proxy for socioeconomic status. Because we were modeling the total association between PFAS and aBMD *z*-score, we did not adjust for any measures of body composition, which were on the hypothesized causal path. The directed acyclic graph (DAG) for our models is included as Fig. 1. We evaluated possible effect modification by sex in a second set of models that included an interaction term between sex and PFAS concentration. We used these interaction models to estimate sex-specific PFAS associations and test whether differences by sex were significant (*p*-interaction  $<0.1$ ).


We also estimated the controlled direct effect of PFAS on aBMD *z*-score by adjusting each model for age-9 total fat mass (g), total lean mass (g), and BMI (kg/m<sup>2</sup>) separately. The direct effect models were also adjusted for physical activity (hours/week), which may be associated with body composition and bone density [40].

### Sensitivity analyses

We conducted several analyses to assess whether our estimates of total association were sensitive to model specification. First, we added an additional adjustment for exclusive breastfeeding duration (months) to our models of PFAS exposure at age 18 months, 5 years and 9 years, as breastfeeding is an important PFAS exposure source [41] and may be associated with aBMD [39]. Second, we assessed whether our primary aBMD *z*-scores were sensitive to bias by using a different set of age- and sex-adjusted reference values for total aBMD (not including head) specific to the Norland XR system [42]. Third, we allowed for nonlinear associations between PFAS and aBMD by fitting generalized additive models (GAMs) with penalized thin-plate splines for each PFAS term, and compared the fit of these non-linear models to their linear counterparts using Akaike Information Criterion (AIC) values [43].

### Mediation analysis

We conducted a formal average causal mediation analysis to investigate whether differences in body composition (total body fat, total lean mass, and BMI) at age 9 years mediated the observed associations between PFAS



**Fig. 1** DAG for PFAS exposures at 9 years

(measured at birth, 18 months, and 5 years) and age-9 aBMD z-scores. First, we tested whether the PFAS exposure was significantly ( $p$ -value  $< 0.05$ ) associated with the mediator, and whether the mediator was significantly associated with aBMD z-score after adjustment for PFAS exposure. Each potential mediation model was evaluated only if these two criteria were met [44]. We then decomposed the total PFAS effect (TE) into two components:

1. The average causal mediated effect (ACME), representing the estimated average change in aBMD that is mediated through changes in body composition; and
2. The average direct effect (ADE), representing the average estimated effect of PFAS exposure on aBMD that is not mediated through changes in body composition.

The percent mediated (PM) was calculated as the ratio of the mediated effect and the total effect (ACME/

TE)  $\times 100\%$ . All mediation models were adjusted for the covariates included in our primary models, as well as for weekly physical activity, which may act as a confounder in the association between body composition and aBMD (Fig. 1). Confidence intervals were calculated using non-parametric bootstrapping ( $n = 1000$ ) [45, 46].

Our primary mediation analysis was limited to mediators measured at age 9, the only time when DXA scans were conducted in this cohort. To address this limitation, we conducted an additional sensitivity analysis to better represent the assumed temporality underlying our mediation analysis. We examined whether BMI measured at age 5 mediated observed associations between PFAS (measured at birth and 18 months) and aBMD z-scores.

All statistical analyses were conducted in R version 4.2.1 (2022-06-23) [47]. DAGs were drawn using the packages “dagitty” version 0.3.1 and “ggdag” version 0.2.6 [48, 49]. Causal mediation analyses were completed using the mediation package version 4.5.0 [46].

### Results

A total of 366 participants (75%) from the original birth cohort had DXA measurements at age 9, PFAS concentrations measured from one or more visits, and complete covariate information (Fig. S1 and Table S1). Children with age-9 DXA scans were generally similar to the overall study population (Table S2), although there was a significant difference in maternal education where children with a DXA scan had a higher percentage of mothers with a medium-level education, while children without a DXA scan had a higher percentage of mothers with either a low or high education level. Maternal and child characteristics for this population are shown in Table 1. Our study population was 52% male, and most children had older siblings (72%). The average age at the DXA visit was 9.07 years (SD: 0.14). Population characteristics were

similar in females and males, except that males reported higher physical activity at age 9 years (Table S3). Population characteristics were also similar across the subsets of study participants with measured PFAS concentrations at each time point (Table S4).


Serum-PFAS concentrations were above the LOD in 99% of the serum samples. Concentrations of PFOA and PFOS showed a maximum at 18 months, while concentrations of PFDA, PFHxS and PFNA were the highest at age 5 years (Fig. S2 and Table S5). Cord blood serum concentrations at birth varied significantly by some population characteristics. For example, first-born children had higher PFAS concentrations for all measured PFAS compounds, and children born to mothers who reported smoking during pregnancy had higher concentrations of PFOA and PFHxS (Table S6).

Concentrations of different PFAS compounds were correlated within visit. For example, PFNA and PFDA showed a correlation of 0.85 at birth, 0.89 at 18 months, and 0.87 at 9 years. Concentrations of individual PFAS compounds were also correlated across time. For example, PFOS at age 9 had a correlation of 0.81 with PFOS at age 5 and 0.81 with PFOS at 18 months (Fig. S3).

Higher concentrations of PFOA and PFNA at age 5 years were associated with decreased aBMD z-scores at age 9 (Fig. 2 and Table S7). A doubling in age-5 PFNA concentrations was associated with a -0.15 decrease in aBMD z-score (95% CI: -0.26, -0.039), while a doubling in age-5 PFOA concentrations was associated with a -0.16 decrease in aBMD z-score (95% CI: -0.33, 0.0086). PFNA concentrations measured at age 18 months were also marginally associated with decreased aBMD z-scores at age 9, which other PFAS concentrations at age 18 months were consistently but non-significantly associated with aBMD z-scores. We did not find any associations between

**Table 1** Characteristics of the Faroese mother-child pairs

Characteristic	Level	N (%) or Mean (SD)
N		366
Sex	Female	177 (48.4)
	Male	189 (51.6)
Maternal education	Low	117 (32.0)
	Medium	103 (28.1)
	High	146 (39.9)
Maternal smoking	Yes	60 (16.4)
	No	306 (83.6)
Parity	Primiparous	104 (28.4)
	Multiparous	262 (71.6)
Maternal pre-pregnancy BMI (kg/m <sup>2</sup> )		24.41 (4.48)
Weekly physical activity, hours	≤ 1	86 (23.5)
	2–3	199 (54.4)
	≥ 4	81 (22.1)



**Fig. 2** Associations between aBMD and PFAS concentrations at birth, 18 months, age 5 and age 9

PFAS concentrations measured at birth or at age 9 and aBMD z-scores. Effect modification by sex was marginally significant for PFNA exposures at age 5 years ( $p$ -interaction=0.11), where the effect in males was stronger than in females (Fig. S4). Otherwise, effect modification by sex was non-significant.

When we estimated the controlled direct effect of PFAS exposures on aBMD z-scores by adjusting for BMI and total fat mass, negative PFAS-aBMD associations were attenuated, especially for 18-month PFAS exposures where the estimated direct effect was near zero. The direct associations after adjustment for total lean mass were generally more similar to the estimated total associations (Fig. S5).

When we further adjusted our primary models for the duration of exclusive breastfeeding, the estimated associations remained consistent with our primary results (Fig. S6). In our second sensitivity analysis using age- and sex-adjusted aBMD z-scores rather than age-, sex-, and height-adjusted aBMD z-scores, we found stronger negative associations between PFAS exposures at age 5 years and aBMD z-scores (Fig. S7). Finally, most linear models (65%) fit better than non-linear models when compared using AIC values. Of the seven models that fit better with non-linear splines, only one showed a significant effect of non-linear PFAS (PFOA exposure at age 18 months). However, the fit appeared linear across most of the distribution of serum-PFAS concentrations (Fig. S8).


We evaluated whether body composition could mediate the effect of PFAS on aBMD using three measures of body composition measured at age 9 years, i.e., BMI, total

body fat and total lean mass. Of the possible mediation models considered, BMI was significantly associated with 18-month PFDA, PFNA, and PFOA concentrations, as well as 5-year PFOA concentrations. Total body fat was associated with the same exposures, as well as 18-month PFOS concentrations. Total lean mass was not associated with any PFAS exposures. BMI measured at age 5 years was associated with 18-month PFDA and PFNA concentrations. All measures of body composition were associated with aBMD at age 9.

The mediation models generally showed significant ACMEs by BMI and total fat mass between 18-month PFAS and aBMD z-scores, but the total effects for most models were non-significant (Fig. 3 and Table S8). This suggests that any potential associations between 18-month PFAS concentrations and aBMD z-scores may be mediated by body composition. When we evaluated mediation by age-5 BMI for PFNA and PFDA exposures at age 18 months, we found significant ACMEs for both models, as well as a significant total effect for PFNA on aBMD z-score (Fig. S9), where 49% of the total effect of 18-month PFNA on aBMD z-score was mediated by BMI at age 5.

**Discussion**

This study measured bone mineral density in 366 children at age 9 years and assessed possible associations with PFAS exposures both prenatally and in early- and mid-childhood. We found that age-, sex- and height-adjusted aBMD z-scores showed consistent negative associations with PFAS exposures at 18 months and



**Fig. 3** Mediation analysis of the PFAS-aBMD association by BMI and total body fat

5 years, with the strongest effects found for PFNA and PFOA exposures at age 5. Differences between our primary model using age-, sex-, and height-adjusted aBMD  $z$ -scores and results from a sensitivity analysis using only age- and sex-adjusted  $z$ -scores indicate the importance of accounting for height as a possible confounder, especially given the known close relationship between prepuberty bone mass and height [13, 50].

We hypothesized that any PFAS-aBMD association may be mediated by body composition, specifically BMI, total body fat, and/or lean mass, which have been associated with PFAS exposures both in the present cohort and in other studies [22–24, 51]. Results from our mediation models suggest that 18-month PFAS exposures may affect both aBMD and body composition, although the lack of a strong total effect limits the conclusions that can be drawn from this analysis. In contrast, age-5 PFAS exposures were generally not associated with body composition. While the present study does not explore the possible pathogenesis of decreased bone mineral content, our results may indicate that different mechanisms may be in operation for PFAS exposures at different developmental stages.

These findings are meaningful in the light of experimental evidence. Reduced ossification occurred in neonatal mice at low PFOA doses that did not affect fetal weight, suggesting that ossification abnormalities may represent a specific toxicity(s) rather than developmental delays [52]. PFAS act as peroxisome proliferator-activated receptor (PPAR) agonists, which are expressed in osteoclasts and osteoblasts and may impact osteogenic differentiation [2, 5, 53, 54]. Furthermore, PFAS may inhibit enzyme activity on androgen secretion pathways [55] or act as androgen receptor antagonists [7, 56], which may impact bone formation. A recent study found that PFOA may act as an antagonist on the Vitamin D receptor [4], possibly contributing to a functional vitamin D deficiency. Taken together, this evidence indicates that PFAS exposures could affect bone ossification via several biological mechanisms. Given this background, the U.S. Agency for Toxic Substances and Disease Registry chose the experimental data on skeletal toxicity [5] as the criterion for identifying a Minimal Risk Level for PFOA [57].

Our results add to several previous studies that also found associations between developmental PFAS exposures and bone health in children. Two longitudinal studies have evaluated associations between prenatal PFAS exposures and indicators of childhood and adolescence bone health. One found an inverse association between prenatal PFOS exposure and BMD measured at age 17 years, although the association was null after adjustment for height [19]. The second study found inverse associations between prenatal PFOA and PFNA

and age-12 BMC  $z$ -scores for the hip and forearm, but no associations with TBLH age-, sex-, race- and height-adjusted BMC and aBMD  $z$ -scores [18]. In comparison, our study did not find an association between any prenatal PFAS exposures and age-9 aBMD  $z$ -scores. However, both previous studies estimated prenatal exposures using maternal serum-PFAS concentrations from pregnancy, while we assessed prenatal exposures using cord serum-PFAS concentrations from delivery. Although closely correlated, these different exposure measurements are not entirely comparable because maternal serum concentrations may change during the course of pregnancy and not only reflect prenatal exposures, but may also contribute to infancy exposures via transfer by breastmilk [41, 58].

Three additional studies evaluated cross-sectional associations in childhood. In a small pilot study of children aged 8–12 ( $n=48$ ), PFAS were associated with non-significant decreases in several parameters of bone health, with the strongest associations found for PFNA [15]. A larger cross-sectional study of children ( $n=576$ , mean age=8) similarly found that higher plasma-PFAS concentrations were associated with lower aBMD age-, sex-, and height-adjusted  $z$ -scores, with the strongest and most consistent association found for PFOA [16]. Finally, a third cross-sectional study of adolescents ages 12–19 years using data from NHANES 2011–2016 ( $n=848$ ) found that an increase in PFOA and the overall PFAS mixture was associated with a decrease in age-, sex-, and height-adjusted aBMD  $z$ -scores in males but not females [17]. Compared to these cross-sectional studies, we found stronger associations between aBMD and earlier childhood serum-PFAS concentrations measured at ages 18 months and 5 years. Our study is the first to examine PFAS exposures in these early years, which may reflect important developmental windows in regard to programming of bone development. Thus, despite the fairly long half-lives of PFAS, identification of the most vulnerable time windows likely requires assessment of PFAS concentrations at different ages.

In regard to limitations, our primary models or mediation models may be potentially impacted by residual confounding (e.g., by socioeconomic status or diet). Given the homogeneity of the Faroese population [25], this concern is probably minor. Our mediation model may also be biased by confounding of the association between body composition and bone density (so-called collider-stratification bias). However, we were able to control for exercise, an important potential cofactor in this regard. Pubertal status is an unlikely confounder as all our measurements were conducted at age 9 years, i.e., pre-puberty in most children. Finally, our mediation analyses were only able to evaluate mediation by total fat mass and total lean mass measured at the same time as

the primary outcome, making it difficult to distinguish whether body composition is really acting as a mediator. To address this, however, we were able to evaluate whether BMI measured at age-5 was a possible mediator, better representing the temporality assumed in the mediation models [59].

## Conclusions

Our study examines prospective associations between childhood aBMD and PFAS exposure profiles measured longitudinally across childhood development. We assessed pediatric bone density using the recommended measurement of age-, sex-, and height-adjusted TBLH aBMD *z*-score. Pediatric bone density has been shown to strongly track from childhood through young adulthood and predict peak bone mass [11, 60–62]. Peak bone mass, in turn, is an important determinant of future risk of osteoporosis [12, 13]. While further studies are needed to evaluate associations of PFAS exposures with clinical outcomes like fractures, the consistent associations found in this and previous studies support the possibility that bone may be a target tissue for developmental PFAS toxicity in humans.

## Abbreviations

aBMD	Areal bone mineral density
PFAS	Perfluoroalkyl substance
PFOS	Perfluorooctanesulfonic acid
PFOA	Perfluorooctanoic acid
PFFhS	Perfluorohexanesulfonic acid
PFNA	Perfluorononanoic acid
PFDA	Perfluorodecanoic acid
TBLH	Total body less head
DAG	Directed acyclic graph
TE	Total effect
ADE	Average direct effect
ACME	Average causal mediated effect

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12940-022-00929-w>.

**Additional file 1: Table S1.** Count of Missing Covariates. **Table S2.** Baseline covariates for mother-child pairs in the Faroe Island Cohort 5, stratified by whether or not the child completed a DXA scan at age 9. **Table S3.** Baseline covariates of study participants, stratified by sex. **Table S4.** Baseline covariates of study participants, stratified by the time point of PFAS exposure measurement. **Table S5.** PFAS concentrations (ng/ml) by visit. **Table S6.** PFAS concentrations at birth (ng/ml) by study covariates. **Table S7.** Estimated total association between serum PFAS concentrations and aBMD at age 9, presented as the expected difference in aBMD for a doubling in serum PFAS. **Table S8.** Estimated ADE and ACME from causal mediation models. **Fig. S1.** Study selection flow chart. **Fig. S2.** Distribution of serum PFAS concentrations by visit. **Fig. S3.** Correlation of serum PFAS concentrations. **Fig. S4.** Associations between PFAS exposures measured at birth, 18 months, age 5 and age 9 and aBMD *z*-scores measured at age 9 by sex. **Fig. S5.** Direct and total associations between PFAS exposures measured at birth, 18 months, age 5, and age 9 and aBMD *z*-scores measured at age 9. **Fig. S6.** Associations between PFAS exposures measured at 18 months, and age 5 and 9 years and aBMD *z*-scores measured at age

9 years, with and without additional adjustment for duration of exclusive breastfeeding. **Fig. S7.** Comparison of associations between PFAS and age-, sex- and height-adjusted aBMD *z*-scores (primary outcome) vs. age- and sex-adjusted aBMD *z*-scores. **Fig. S8.** Estimated thin-plate splines for significant nonlinear PFAS terms. **Fig. S9.** Mediation of the association between 18-month PFNA and PFDA concentrations and aBMD *z*-scores by BMI measured at age 5 years, limited to the 244 study participants who have 18-month PFAS measurements, 9-year DXA scans, complete covariate information and BMI values measured at age 5 years.

## Acknowledgements

We would like to acknowledge the cohort families for their committed participation and support. We would also like to thank the reviewers and editors of this manuscript for their constructive suggestions and comments.

## Authors' contributions

AJB designed the analysis plan, conducted statistical analyses, created tables and visuals, participated in writing the original draft and reviewed and edited the paper. JM contributed to the analysis plan, provided DXA expertise, and reviewed and edited the paper. PW contributed to the analysis plan, oversaw the investigation, and contributed funding. PG contributed to the analysis plan, was a significant contributor in writing the draft and final paper, contributed funding and supervised the project. All authors read and approved the final manuscript.

## Authors information

Not applicable.

## Funding

This work was supported by the National Institute of Environmental Health Sciences (grant numbers ES026596 and ES027706) and the Danish Environmental Protection Agency as part of the Danish Cooperation for Environment in the Arctic (DANCEA). The authors are solely responsible for all results and conclusions, which do not necessarily reflect the position of any of the funding agencies.

## Availability of data and materials

The Faroe Island Cohort 5 data are available to collaborating scientists following strict data privacy protocols, in respect of the GDPR.

## Declarations

### Ethics approval and consent to participate

This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The Harvard T.H. Chan institutional review board and the Faroese ethical review committee approved the study protocol, and written informed consent was obtained from all mothers.

### Consent for publication

Not applicable.

### Competing interests

PG has served as a health expert in lawsuits on environmental PFAS exposures. PG is an Editor-in-Chief of *Environmental Health* but was not involved in the editorial processing of the present manuscript. All other authors have no competing interests to declare, financial or otherwise.

Received: 1 March 2022 Accepted: 2 October 2022

Published online: 19 November 2022

## References

1. Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects.

- J Expo Sci Environ Epidemiol. 2019;29:131–47. <https://doi.org/10.1038/s41370-018-0094-1>.
2. Koskela A, Koponen J, Lehenkari P, Viluksela M, Korkalainen M, Tuukkanen J. Perfluoroalkyl substances in human bone: concentrations in bones and effects on bone cell differentiation. *Sci Rep*. 2017;7:6841. <https://doi.org/10.1038/s41598-017-07359-6>.
  3. Pérez F, Nadal M, Navarro-Ortega A, Fàbrega F, Domingo JL, Barceló D, et al. Accumulation of perfluoroalkyl substances in human tissues. *Environ Int*. 2013;59:354–62. <https://doi.org/10.1016/j.envint.2013.06.004>.
  4. Di Nisio A, Rocca MS, De Toni L, Sabovic I, Guidolin D, Dall'Acqua S, et al. Endocrine disruption of vitamin D activity by perfluoro-octanoic acid (PFOA). *Sci Rep*. 2020;10:16789. <https://doi.org/10.1038/s41598-020-74026-8>.
  5. Koskela A, Finnilä MA, Korkalainen M, Spulber S, Koponen J, Håkansson H, et al. Effects of developmental exposure to perfluorooctanoic acid (PFOA) on long bone morphology and bone cell differentiation. *Toxicol Appl Pharmacol*. 2016;301:14–21. <https://doi.org/10.1016/j.taap.2016.04.002>.
  6. Banjabi AA, Li AJ, Kumosani TA, Yousef JM, Kannan K. Serum concentrations of perfluoroalkyl substances and their association with osteoporosis in a population in Jeddah, Saudi Arabia. *Environ Res*. 2020;187:109676. <https://doi.org/10.1016/j.envres.2020.109676>.
  7. Di Nisio A, Sabovic I, Valente U, Tesconi S, Rocca MS, Guidolin D, et al. Endocrine disruption of androgenic activity by Perfluoroalkyl substances: clinical and experimental evidence. *J Clin Endocrinol Metab*. 2019;104:1259–71. <https://doi.org/10.1210/je.2018-01855>.
  8. Hu Y, Liu G, Rood J, Liang L, Bray GA, de Jonge L, et al. Perfluoroalkyl substances and changes in bone mineral density: a prospective analysis in the POUNDS-LOST study. *Environ Res*. 2019;179:108775. <https://doi.org/10.1016/j.envres.2019.108775>.
  9. Khalil N, Chen A, Lee M, Czerwinski SA, Ebert JR, DeWitt JC, et al. Association of Perfluoroalkyl Substances, bone mineral density, and osteoporosis in the U.S. population in NHANES 2009–2010. *Environ Health Perspect*. 2016;124:81–7. <https://doi.org/10.1289/ehp.1307909>.
  10. Lin L-Y, Wen L-L, Su T-C, Chen P-C, Lin C-Y. Negative association between serum Perfluorooctane sulfate concentration and bone mineral density in US premenopausal women: NHANES, 2005–2008. *J Clin Endocrinol Metab*. 2014;99:2173–80. <https://doi.org/10.1210/jc.2013-3409>.
  11. Gordon CM, Zemel BS, Wren TAL, Leonard MB, Bachrach LK, Rauch F, et al. The determinants of peak bone mass. *J Pediatr*. 2017;180:261–9. <https://doi.org/10.1016/j.jpeds.2016.09.056>.
  12. Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, et al. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. *Osteoporos Int*. 2016;27:1281–386. <https://doi.org/10.1007/s00198-015-3440-3>.
  13. Bonjour J-P, Theintz G, Law F, Slosman D, Rizzoli R. Peak bone mass. *Osteoporos Int*. 1994;4:57–13. <https://doi.org/10.1007/BF01623429>.
  14. Khalil N, Koskela A. Bone as a target for endocrine disruptors. *Chall. Endocr Disruptor Toxicol Risk Assess*. 2020;42:218 Royal Society of Chemistry.
  15. Khalil N, Ebert JR, Honda M, Lee M, Nahhas RW, Koskela A, et al. Perfluoroalkyl substances, bone density, and cardio-metabolic risk factors in obese 8–12 year old children: a pilot study. *Environ Res*. 2018;160:314–21. <https://doi.org/10.1016/j.envres.2017.10.014>.
  16. Cluett R, Seshasayee SM, Rokoff LB, Rifas-Shiman Sheryl L, Ye X, Calafat AM, et al. Per- and Polyfluoroalkyl substance plasma concentrations and bone mineral density in Midchildhood: a cross-sectional study (project viva, United States). *Environ Health Perspect*. 2019;127:087006. <https://doi.org/10.1289/EHP4918>.
  17. Carwile JL, Seshasayee SM, Ahrens KA, Hauser R, Driban JB, Rosen CJ, et al. Serum PFAS and urinary phthalate biomarker concentrations and bone mineral density in 12–19 year olds: 2011–2016 NHANES. *J Clin Endocrinol Metab*. 2022;107:e3343–52. <https://doi.org/10.1210/clinem/dgac228>.
  18. Buckley JP, Kuiper JR, Lanphear BP, Calafat AM, Cecil KM, Chen A, et al. Associations of maternal serum Perfluoroalkyl substances concentrations with early adolescent bone mineral content and density: the health outcomes and measures of the environment (HOME) study. *Environ Health Perspect*. 2021;129:097011. <https://doi.org/10.1289/EHP9424>.
  19. Jeddy Z, Tobias JH, Taylor EV, Northstone K, Flanders WD, Hartman TJ. Prenatal concentrations of perfluoroalkyl substances and bone health in British girls at age 17. *Arch Osteoporos*. 2018;13:84. <https://doi.org/10.1007/s11657-018-0498-5>.
  20. Clark EM, Ness AR, Tobias JH. Adipose tissue stimulates bone growth in Prepubertal children. *J Clin Endocrinol Metab*. 2006;91:2534–41. <https://doi.org/10.1210/jc.2006-0332>.
  21. Timpson NJ, Sayers A, Davey-Smith G, Tobias JH. How does body fat influence bone mass in childhood? A Mendelian randomization approach. *J Bone Miner Res*. 2009;24:522–33. <https://doi.org/10.1359/jbmr.081109>.
  22. Braun JM, Eliot M, Papandonatos GD, Buckley JP, Cecil KM, Kalkwarf HJ, et al. Gestational perfluoroalkyl substance exposure and body mass index trajectories over the first 12 years of life. *Int J Obes (Lond)*. 2021;45:25–35. <https://doi.org/10.1038/s41366-020-00717-x>.
  23. Geiger SD, Yao P, Vaughn MG, Qian Z. PFAS exposure and overweight/obesity among children in a nationally representative sample. *Chemosphere*. 2021;268:128852. <https://doi.org/10.1016/j.chemosphere.2020.128852>.
  24. Karlsen M, Grandjean P, Weihe P, Steuerwald U, Oulhote Y, Valvi D. Early-life exposures to persistent organic pollutants in relation to overweight in preschool children. *Reprod Toxicol*. 2017;68:145–53. <https://doi.org/10.1016/j.reprotox.2016.08.002>.
  25. Weihe P, Dam M, Olafsson Á. The Faroe Islands: sociocultural environment, lifestyle, health and contaminant exposure. In: Deutch B, Hansen JC, editors. *AMAP GreenL. Faroe Isl. 1997–2001*, vol. 1: Human Health, Danish Environmental Protection Agency; 2003. p. 123–34.
  26. Grandjean P, Heilmann C, Weihe P, Nielsen F, Mogensen UB, Timmermann A, et al. Estimated exposures to perfluorinated compounds in infancy predict attenuated vaccine antibody concentrations at age 5-years. *J Immunotoxicol*. 2017;14:188–95. <https://doi.org/10.1080/1547691X.2017.1360968>.
  27. Weihe P, Bjerregaard P, Bonefeld-Jørgensen E, Dudarev AA, Halling J, Hansen S, et al. Overview of ongoing cohort and dietary studies in the Arctic. *Int J Circumpolar Health*. 2016;75:33803. <https://doi.org/10.3402/ijch.v75.33803>.
  28. Haug LS, Thomsen C, Becher G. A sensitive method for determination of a broad range of perfluorinated compounds in serum suitable for large-scale human biomonitoring. *J Chromatogr A*. 2009;1216:385–93. <https://doi.org/10.1016/j.chroma.2008.10.113>.
  29. Zemel BS, Kalkwarf HJ, Gilsanz V, Lappe JM, Oberfield S, Shepherd JA, et al. Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: results of the bone mineral density in childhood study. *J Clin Endocrinol Metab*. 2011;96:3160–9. <https://doi.org/10.1210/jc.2011-1111>.
  30. International Society for Clinical Densitometry. *Skeletal health assessment in children from infancy to adolescence: 2019 ISCD official positions pediatric*. Middletown: The International Society for Clinical Densitometry (ISCD); 2019. [www.ISCD.org](http://www.ISCD.org).
  31. Bjerregaard-Olesen C, Bach CC, Long M, Ghisari M, Bech BH, Nohr EA, et al. Determinants of serum levels of perfluorinated alkyl acids in Danish pregnant women. *Int J Hyg Environ Health*. 2016;219:867–75. <https://doi.org/10.1016/j.ijheh.2016.07.008>.
  32. Brantsæter AL, Whitworth KW, Ydersbond TA, Haug LS, Haugen M, Knutsen HK, et al. Determinants of plasma concentrations of perfluoroalkyl substances in pregnant Norwegian women. *Environ Int*. 2013;54:74–84. <https://doi.org/10.1016/j.envint.2012.12.014>.
  33. Harris MH, Rifas-Shiman SL, Calafat AM, Ye X, Mora AM, Webster TF, et al. Predictors of per- and Polyfluoroalkyl substance (PFAS) plasma concentrations in 6–10 year old American children. *Environ Sci Technol*. 2017;51:5193–204. <https://doi.org/10.1021/acs.est.6b05811>.
  34. Kingsley SL, Eliot MN, Kelsey KT, Calafat AM, Ehrlich S, Lanphear BP, et al. Variability and predictors of serum perfluoroalkyl substance concentrations during pregnancy and early childhood. *Environ Res*. 2018;165:247–57. <https://doi.org/10.1016/j.envres.2018.04.033>.
  35. Morck TA, Nielsen F, Nielsen JKS, Siersma VD, Grandjean P, Knudsen LE. PFAS concentrations in plasma samples from Danish school children and their mothers. *Chemosphere*. 2015;129:203–9. <https://doi.org/10.1016/j.chemosphere.2014.07.018>.
  36. Shu H, Lindh CH, Wikström S, Bornehag C-G. Temporal trends and predictors of perfluoroalkyl substances serum levels in Swedish pregnant women in the SELMA study. *PLoS One*. 2018;13:e0209255. <https://doi.org/10.1371/journal.pone.0209255>.

37. Rubin K, Schirduan V, Gendreau P, Sarfarazi M, Mendola R, Dalsky G. Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. *J Pediatr*. 1993;123:863–70. [https://doi.org/10.1016/S0022-3476\(05\)80381-6](https://doi.org/10.1016/S0022-3476(05)80381-6).
38. Harvey NC, Javaid MK, Arden NK, Poole JR, Crozier SR, Robinson SM, et al. Maternal predictors of neonatal bone size and geometry: the Southampton Women's survey. *J Dev Orig Health Dis*. 2010;1:35–41. <https://doi.org/10.1017/S2040174409990055>.
39. Yang Y, Wu F, Dwyer T, Antony B, Winzenberg T, Jones G. Associations of breastfeeding, maternal smoking, and birth weight with bone density and microarchitecture in young adulthood: a 25-year birth-cohort study. *J Bone Miner Res*. 2020;35:1652–9. <https://doi.org/10.1002/jbmr.4044>.
40. Boot AM, de Ridder MAJ, Pols HAP, Krenning EP, de Muinck K-SSMPF. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity\*. *J Clin Endocrinol Metab*. 1997;82:57–62. <https://doi.org/10.1210/jcem.82.1.3665>.
41. Mogensen UB, Grandjean P, Nielsen F, Weihe P, Budtz-Jørgensen E. Breast-feeding as an exposure pathway for perfluorinated alkylates. *Environ Sci Technol*. 2015;49:10466–73. <https://doi.org/10.1021/acs.est.5b02237>.
42. Zanchetta JR, Plotkin H, Filgueira MA. Bone mass in children: normative values for the 2–20-year-old population. *Bone*. 1995;16:S393–9.
43. Wood SN. Stable and efficient multiple smoothing parameter estimation for generalized additive models. *J Am Stat Assoc*. 2004;99:673–86. <https://doi.org/10.1198/016214504000000980>.
44. VanderWeele T. *Explanation in causal Inference: methods for mediation and interaction*. New York: Oxford University Press; 2015. ISBN 9780199325870 / 9780199325887.
45. Imai K, Keele L, Tingley D, Yamamoto T. In: Vinod HD, editor. *Adv. Soc. Sci. Res. Using R Causal mediation analysis using R*. New York: Springer New York; 2010. p. 129–54.
46. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. Mediation: R package for causal mediation analysis. *J Stat Softw*. 2014;59:1–38. <https://doi.org/10.18637/jss.v059.i05>.
47. R Core Team. *R: a language and environment for statistical computing* 2020.
48. Barrett M. Ggdag: analyze and create elegant directed acyclic graphs. R package version 0.2.2; 2020.
49. Textor J, van der Zander B, Gilthorpe MS, Liškievicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package 'dagitty'. *Int J Epidemiol*. 2016;45:1887–94. <https://doi.org/10.1093/ije/dyw341>.
50. Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, et al. Height adjustment in assessing dual energy X-ray absorptiometry measurements of bone mass and density in children. *J Clin Endocrinol Metab*. 2010;95:1265–73. <https://doi.org/10.1210/jc.2009-2057>.
51. Janis JA, Rifas-Shiman SL, Seshasayee SM, Sagiv S, Calafat AM, Gold DR, et al. Plasma concentrations of per- and Polyfluoroalkyl substances and body composition from mid-childhood to early adolescence. *J Clin Endocrinol Metab*. 2021;106:e3760–70. <https://doi.org/10.1210/clinem/dgab187>.
52. Lau C, Thibodeaux JR, Hanson RG, Narotsky MG, Rogers JM, Lindstrom AB, et al. Effects of Perfluorooctanoic acid exposure during pregnancy in the mouse. *Toxicol Sci*. 2006;90:510–8. <https://doi.org/10.1093/toxsci/kfj105>.
53. Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. *Fundam Clin Pharmacol*. 2007;21:231–44. <https://doi.org/10.1111/j.1472-8206.2007.00486.x>.
54. Liu S, Yang R, Yin N, Wang Y-L, Faiola F. Environmental and human relevant PFOS and PFOA doses alter human mesenchymal stem cell self-renewal, adipogenesis and osteogenesis. *Ecotoxicol Environ Saf*. 2019;169:564–72. <https://doi.org/10.1016/j.ecoenv.2018.11.064>.
55. Zhao B, Hu G-X, Chu Y, Jin X, Gong S, Akingbemi BT, et al. Inhibition of human and rat 3 $\beta$ -hydroxysteroid dehydrogenase and 17 $\beta$ -hydroxysteroid dehydrogenase 3 activities by perfluoroalkylated substances. *Chem Biol Interact*. 2010;188:38–43. <https://doi.org/10.1016/j.cbi.2010.07.001>.
56. Kjeldsen LS, Bonfeld-Jørgensen EC. Perfluorinated compounds affect the function of sex hormone receptors. *Environ Sci Pollut Res*. 2013;20:8031–44. <https://doi.org/10.1007/s11356-013-1753-3>.
57. Agency for Toxic Substances and Disease Registry (ATSDR). *Toxicological profile for perfluoroalkyls*. Atlanta: U.S. Department of Health and Human Services, Public Health Service; 2021. <https://doi.org/10.15620/cdc:59198>.
58. Chen L, Tong C, Huo X, Zhang J, Tian Y. Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and birth outcomes: a longitudinal cohort with repeated measurements. *Chemosphere*. 2021;267:128899. <https://doi.org/10.1016/j.chemosphere.2020.128899>.
59. Inoue K, Goto A, Sugiyama T, Ramlau-Hansen CH, Liew Z. The confounder-mediator dilemma: should we control for obesity to estimate the effect of Perfluoroalkyl substances on health outcomes? *Toxics*. 2020;8:125. <https://doi.org/10.3390/toxics8040125>.
60. Fujita Y, Iki M, Ikeda Y, Morita A, Matsukura T, Nishino H, et al. Tracking of appendicular bone mineral density for 6 years including the pubertal growth spurt: Japanese population-based osteoporosis kids cohort study. *J Bone Miner Metab*. 2011;29:208–16. <https://doi.org/10.1007/s00774-010-0213-0>.
61. Nilsen OA, Ahmed LA, Winther A, Christoffersen T, Furberg A-S, Grimnes G, et al. Changes and tracking of bone mineral density in late adolescence: the Tromsø study, fit futures. *Arch Osteoporos*. 2017;12:37. <https://doi.org/10.1007/s11657-017-0328-1>.
62. Wren TAL, Kalkwarf HJ, Zemel BS, Lappe JM, Oberfield S, Shepherd JA, et al. Longitudinal tracking of dual-energy X-ray absorptiometry bone measures over 6 years in children and adolescents: persistence of low bone mass to maturity. *J Pediatr*. 2014;164:1280–1285.e2. <https://doi.org/10.1016/j.jpeds.2013.12.040>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

